IDEXX Laboratories, Inc. reported a significant increase in financial performance for the second quarter of 2026, with total revenue reaching $1.22 billion, a 9.7% increase from $1.11 billion in the same period last year. For the first half of 2026, revenue totaled $2.36 billion, up 11.8% from $2.11 billion in the prior year. The company's net income for the quarter was $338.4 million, or $4.27 per diluted share, compared to $294.0 million, or $3.63 per diluted share, in the second quarter of 2025. The increase in profitability was attributed to higher sales volumes and improved pricing across its product lines, particularly in the Companion Animal Group (CAG) segment.
IDEXX's financial results reflect a strong performance in its CAG segment, which generated $1.12 billion in revenue, a 9.4% increase year-over-year. This growth was driven by a rise in diagnostics recurring revenue, including IDEXX VetLab consumables and reference laboratory services. The Water and Livestock, Poultry, and Dairy (LPD) segments also contributed positively, with revenues of $58.6 million and $35.2 million, respectively, marking increases of 14.8% and 10.8% compared to the previous year. The company noted that foreign currency exchange rates positively impacted revenue growth by approximately 0.7% in the second quarter.
Operationally, IDEXX reported a total of 78,874 shares outstanding as of June 30, 2026, a slight decrease from 79,712 shares at the end of 2025. The company has continued to invest in its workforce, with total employee headcount increasing to support its growth initiatives. The company also reported a cash and cash equivalents balance of $196.9 million, up from $180.1 million at the end of 2025, and maintained a strong liquidity position with $729.2 million available under its $1.25 billion credit facility.
Strategically, IDEXX has focused on expanding its product offerings and enhancing customer engagement. The company has made significant investments in research and development, with expenses rising to $65.4 million in the second quarter, reflecting a commitment to innovation in veterinary diagnostics and software solutions. Additionally, IDEXX has been active in share repurchase programs, having repurchased 582,329 shares in the second quarter, with a total of 2.55 million shares remaining under its authorized repurchase plan.
Looking ahead, IDEXX anticipates continued revenue growth driven by strong demand for its diagnostic products and services, alongside ongoing investments in technology and infrastructure. The company remains optimistic about its ability to navigate macroeconomic challenges, including inflation and currency fluctuations, while maintaining its focus on delivering value to shareholders and customers alike.
About IDEXX LABORATORIES INC /DE
IDEXX Laboratories develops and distributes diagnostic products and services for veterinary, livestock, poultry, water testing, and human medical sectors. Its core offerings include in-clinic and reference laboratory diagnostics, practice management software, imaging systems, and water microbiology tests. Serving global markets, IDEXX emphasizes innovation, integrated technology, and quality to enhance animal and human health, practice efficiency, and environmental safety. Its business model centers on product development, manufacturing, and worldwide distribution.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov